Publication: Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction
Issued Date
2013-03-01
Resource Type
ISSN
15322157
07487983
07487983
Other identifier(s)
2-s2.0-84874115664
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
European Journal of Surgical Oncology. Vol.39, No.3 (2013), 260-265
Suggested Citation
M. C. Kneubil, J. Brollo, E. Botteri, G. Curigliano, N. Rotmensz, A. Goldhirsch, V. Lohsiriwat, A. Manconi, S. Martella, B. Santillo, J. Y. Petit, M. Rietjens Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction. European Journal of Surgical Oncology. Vol.39, No.3 (2013), 260-265. doi:10.1016/j.ejso.2012.12.004 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/32456
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction
Other Contributor(s)
Abstract
Background: A small but significant proportion of patients with breast cancer (BC) will develop loco-regional recurrence (LRR) after immediate breast reconstruction (IBR). The LRR also varies according to breast cancer subtypes and clinicopathological features. Methods: We studied 1742 consecutive BC patients with IBR between 1997 and 2006. According to St Gallen conference consensus 2011, its BC approximations were applied to classify BC into five subtypes: estrogen receptor (ER) and/or progesterone receptor (PgR) positive, HER2 negative, and low Ki67 (<14%) [luminal A]; ER and/or PgR positive, HER2 negative and high Ki67(≥14%) [luminal B/HER2 negative]; ER and/or PgR positive, any Ki67 and HER2 positive [luminal B/HER2 positive]; ER negative, PgR negative and HER2 positive [HER2 positive/nonluminal]; and ER negative, PgR negative and HER2 negative [triple negative]. Cumulative incidences of LRR were compared across different subgroups by means of the Gray test. Multivariable Cox regression models were applied. Results: Median follow up time was 74 months (range 3-165). The cumulative incidence of LRR was 5.5% (121 events). The 5-year cumulative incidence of LRR was 2.5% for luminal A; 5.0% for luminal B/HER2 negative; 9.8% for luminal B/HER2 positive; 3.8% for HER2 non luminal; and 10.9% for triple negative. On multivariable analysis, tumor size (pT) >2 cm, body mass index (BMI) ≥25, triple negative and luminal B/HER2 positive subtypes were associated with increased risk of LRR. Conclusion: Luminal B/HER2 positive, triple negative subtypes and BMI ≥25 are independent prognostic factors for risk of LRR after IBR. © 2012 Published by Elsevier Ltd.